~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Thursday, June 29, 2017
Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis
Click here to receive MS news via e-mail
Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Commission approve the tablets.
“The positive opinion from the CHMP [the committee] is an extraordinary development for our company, affirming our belief in cladribine tablets as a potential important treatment option for patients living with multiple sclerosis,” Belén Garijo, a Merck board member, said in a press release.
“We now eagerly await the European Commission decision, and the opportunity to make a difference in the MS treatment paradigm,” he said. “Our sincerest thanks to the entire MS community for their unwavering support throughout the cladribine tablets journey.”
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis.
Join us by registering here: www.register.msviewsandnews.org